Maternity hospitals in Manaus, Brazil, have initiated the administration of nirsevimab, a new single-dose antibody treatment designed to prevent infections from respiratory syncytial virus (RSV) in infants. This change aims to gradually replace the previously used palivizumab, which necessitates monthly injections during the RSV circulation period. This adjustment is set to enhance the protection offered to vulnerable children, including premature infants and those under the age of two with pre-existing conditions that increase the risk of respiratory complications.

According to the Amazonas State Health Department, the introduction of nirsevimab is an important public health development as RSV is a leading cause of hospitalization among young children, potentially leading to serious illnesses such as bronchiolitis and pneumonia. The new treatment not only simplifies the vaccination process but also offers a more reliable means of safeguarding at-risk infants against respiratory infections, especially during RSV season.

In preparation for the rollout of nirsevimab, the Dona Lindu Women's Institute in Manaus has trained medical personnel involved in neonatal care, including pediatric specialists. This training ensures that healthcare professionals are equipped with the necessary knowledge and skills to effectively administer the new treatment and monitor its impact on infant health. The move represents a significant step forward in enhancing neonatal care in the region and ensuring better health outcomes for the most vulnerable infants.